IL-6 Reporter HEK-293 Cell Line

Description

Interleukin-6 (IL-6) is an important pro-inflammatory cytokine released during infection or tissue damage, promoting innate and acquired immune responses. IL-6 is rapidly expressed by cells of the natural immune system, such as macrophages, upon encountering damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), as part of the host defense strategy to clear infected cells or damaged tissue. However, excessive production of IL-6 can lead to the development of chronic inflammatory diseases (such as rheumatoid arthritis) and cytokine storms, occurring in patients undergoing CAR-T therapy and various diseases including infections like SARS-CoV-2. Humanized IL-6R antibody tocilizumab targeting the IL-6 pathway has been approved for treating cytokine storms induced by CAR-T cell therapy. The efficacy of tocilizumab in addressing cytokine storms induced by SARS-CoV-2 infection has also been validated. Therefore, inhibiting IL-6 signaling is beneficial for treating cytokine storms.IL-6 exerts its effects through three different signaling pathways: classical signaling, trans-signaling, and trans-presentation. In classical signaling, IL-6 binds to the complex of mIL-6R and gp130, subsequently transducing signals by activating the JAK-STATs pathway. In trans-signaling, IL-6 binds to soluble sIL-6R present in serum and tissue fluids. In trans-presentation, dendritic cells present IL-6 to T cells expressing gp130 on their surface after binding IL-6 to mIL-6R. This alternating action of IL-6 signaling is a critical event in initiating Th17 (T helper 17) cells.AcceGen’s IL-6 Reporter 293 Cell Line is a luciferase reporter cell line constructed based on the STATs signaling pathway. Upon IL-6 binding to IL-6Rα and GP130 receptors, the STATs signaling pathway is activated, leading to the expression of luciferase. The luciferase readout represents the activation effect of the signaling pathway and can thus be used for in vitro evaluation of IL-6-related drugs.